This bulletin covers aspects of lung cancer and should be of interest to multidisciplinary teams working in this area.
Sections can include:
· Combined Modality Therapies
· Drug Therapy
· Pathology, Staging, Polymorphisms & Biomarkers
· Prognosis, Survival & Risk Factors
· Radiotherapy & Imaging
· Supportive Care & Symptom Management
· Surgery
· Tobacco & Smoking
Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285,
General
Boxer, M.M., Duggan, K.J., Descallar, J., et al. (2016). Do patients discussed at a lung cancer multidisciplinary team meeting receive guideline-recommended treatment?. Asia-Pacific Journal of Clinical Oncology 12,1:52-60.
Corre, R., Greillier, L., Le Caer, H., et al. (2016). Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. Journal of Clinical Oncology 34,13:1476-1483.
DVLA. Renal and respiratory disorders: assessing fitness to drive (Mar 2016)
Vinas, F., Ben Hassen, I., Jabot, L., et al. (2016). Delays for diagnosis and treatment of lung cancers: a systematic review. The clinical respiratory journal 10,3:267-271.
Combined Modality Therapies
Antoni, D. and Mornex, F. (2016). Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives. Current opinion in oncology 28,2:104-109.
Brade, A., MacRae, R., Laurie, S.A., et al. (2016). Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer. Clinical Lung Cancer 17,2:133-141.
Chaft, J.E., Dunphy, M., Naidoo, J., et al. (2016). Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 11,4:537-544.
Dudani, S., Leighl, N.B., Ho, C., et al. (2016). Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists. Lung Cancer 94,74-80.
Faivre-Finn, C., Falk, S., Ashcroft, L., et al. (2016). Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. BMJ Open 6,1:e009849.
Hoppe, B.S., Henderson, R., Pham, D., et al. (2016). A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. International journal of radiation oncology, biology, physics 95,1:517-522.
Schild, S.E. and Vokes, E.E. (2016). Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Annals of Oncology 27,4:590-599.
Senan, S., Brade, A., Wang, L., et al. (2016). PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 34,9:953-962.
Swaminath, A., Wright, J.R., Tsakiridis, T.K., et al. (2016). A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non-Small-Cell Lung Cancer. Clinical Lung Cancer 17,2:142-149.
Walraven, I., van den Heuvel, M., van Diessen, J., et al. (2016). Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiotherapy & Oncology 118,3:442-446.
Drug & Targeted Therapy
Abdelraouf, F., Smit, E., Hasan, B., et al. (2016). Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061). European journal of cancer 54,35-39.
Guetz, G.D., Landre, T., Uzzan, B., et al. (2016). Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted Oncology 11,1:41-47.
Herbst, R.S., Baas, P., Kim, D., et al. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387,10027:1540-1550.
Kazandjian, D., Suzman, D.L., Blumenthal, G., et al. (2016). FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Oncologist 21,5:634-642.
Li, G., Gao, S., Sheng, Z., et al. (2016). The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials. Chemotherapy 61,4:179-189.
Lim, S.M., Cho, B.C., Kim, S., et al. (2016). A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung Cancer 93,1-8.
Liu, J., Sheng, Z., Zhang, Y., et al. (2016). The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials. Targeted Oncology 11,1:49-58.
Macbeth, F., Noble, S., Evans, J., et al. (2016). Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. Journal of Clinical Oncology 34,5:488-494.
Mayor, M., Yang, N., Sterman, D., et al. (2016). Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. European Journal of Cardio-Thoracic Surgery 49,5:1324-1333.
Melosky, B., Chu, Q., Juergens, R., et al. (2016). Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. Journal of Clinical Oncology 34,14:1676-1688.
Ou, S.I., Ahn, J.S., De Petris, L., et al. (2016). Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology 34,7:661-668.
Ou, W., Li, N., Wang, S., et al. (2016). Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001). Cancer 122,5:740-747.
Perol, M., Ciuleanu, T., Arrieta, O., et al. (2016). Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer 93,95-103.
Poudel, A., Sinha, S. and Gajra, A. (2016). Navigating the Challenges of Adjuvant Chemotherapy in Older Patients with Early-Stage Non-Small-Cell Lung Cancer. Drugs & aging 33,4:223-232.
Reck, M., Heigener, D. and Reinmuth, N. (2016). Immunotherapy for small-cell lung cancer: emerging evidence. Future Oncology 12,7:931-943.
Schuler, M., Yang, J.C., Park, K., et al. (2016). Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology 27,3:417-423.
Takeda, M., Yamanaka, T., Seto, T., et al. (2016). Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial. Cancer 122,7:1050-1059.
Vavala, T., Follador, A., Tiseo, M., et al. (2016). BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. Lung Cancer 95,73-81.
Wink, K.C.J., Belderbos, J.S.A., Dieleman, E.M.T., et al. (2016). Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiotherapy & Oncology 118,3:453-459.
Yao, J.C., Fazio, N., Singh, S., et al. (2016). Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387,10022:968-977.
Pathology, Staging, Polymorphisms & Biomarkers
Detterbeck, F.C., Bolejack, V., Arenberg, D.A., et al. (2016). The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 11,5:681-692.
Detterbeck, F.C., Franklin, W.A., Nicholson, A.G., et al. (2016). The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 11,5:651-665.
Fu, Z., Peng, Y., Cao, L., et al. (2016). Correlations Between Serum IL-6 Levels and Radiation Pneumonitis in Lung Cancer Patients: A Meta-Analysis. Journal of clinical laboratory analysis 30,2:145-154.
Martin, L.W., D'Cunha, J., Wang, X., et al. (2016). Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). Journal of Clinical Oncology 34,13:1484-1491.
Pedersen, J.H., Saghir, Z., Wille, M.M.W., et al. (2016). Ground-Glass Opacity Lung Nodules in the Era of Lung Cancer CT Screening: Radiology, Pathology, and Clinical Management. Oncology (Williston Park) 30,3:266-274.
Quaife, S.L., Ruparel, M., Beeken, R.J., et al. (2016). The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and 'hard-to-reach' patients. BMC Cancer 16,1:281.
Shea, M., Costa, D.B. and Rangachari, D. (2016). Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Therapeutic Advances in Respiratory Disease 10,2:113-129.
Prognosis, Survival & Risk Factors
Abu-Hejleh, T., Chrischilles, E.A., Halfdanarson, T.R., et al. (2016). The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. American Journal of Clinical Oncology 39,2:126-131.
Brambilla, E., Le Teuff, G., Marguet, S., et al. (2016). Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 34,11:1223-1230.
Radiotherapy & Imaging
Balekian, A.A., Fisher, J.M. and Gould, M.K. (2016). Brain Imaging for Staging of Patients With Clinical Stage IA Non-small Cell Lung Cancer in the National Lung Screening Trial: Adherence With Recommendations From the Choosing Wisely Campaign. Chest 149,4:943-950.
Chang, J.Y., Jabbour, S.K., De Ruysscher, D., et al. (2016). Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. International journal of radiation oncology, biology, physics 95,1:505-516.
Chiang, A., Thibault, I., Warner, A., et al. (2016). A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis. Radiotherapy & Oncology 118,3:478-484.
Gronberg, B.H., Halvorsen, T.O., Flotten, O., et al. (2016). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncologica 55,5:591-597.
Haslett, K., Franks, K., Hanna, G.G., et al. (2016). Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. BMJ Open 6,4:e010457.
Hayes, S.A., Pietanza, M.C., O'Driscoll, D., et al. (2016). Comparison of CT volumetric measurement with RECIST response in patients with lung cancer. European Journal of Radiology 85,3:524-533.
Kamran, S.C., Mueller, B.S., Paetzold, P., et al. (2016). Multi-criteria optimization achieves superior normal tissue sparing in a planning study of intensity-modulated radiation therapy for RTOG 1308-eligible non-small cell lung cancer patients. Radiotherapy & Oncology 118,3:515-520.
Karube, M., Yamamoto, N., Nakajima, M., et al. (2016). Single-Fraction Carbon-Ion Radiation Therapy for Patients 80 Years of Age and Older With Stage I Non-Small Cell Lung Cancer. International journal of radiation oncology, biology, physics 95,1:542-548.
Mattonen, S.A., Palma, D.A., Johnson, C., et al. (2016). Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment. International journal of radiation oncology, biology, physics 94,5:1121-1128.
Miller, D.L., Mayfield, W.R., Luu, T.D., et al. (2016). Community-Based Multidisciplinary Computed Tomography Screening Program Improves Lung Cancer Survival. Annals of Thoracic Surgery 101,5:1864-1869.
Movsas, B., Hu, C., Sloan, J., et al. (2016). Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncology 2,3:359-367.
Rossi, M.M.G., Peulen, H.M.U., Belderbos, J.S.A., et al. (2016). Intrafraction Motion in Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer: Intensity Modulated Radiation Therapy Versus Volumetric Modulated Arc Therapy. International journal of radiation oncology, biology, physics 95,2:835-843.
Shaverdian, N., Tenn, S., Veruttipong, D., et al. (2016). The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy. British Journal of Radiology 89,1059:20150963.
Shrimali, R.K., Mahata, A., Reddy, G.D., et al. (2016). Pitfalls and Challenges to Consider before Setting up a Lung Cancer Intensity-modulated Radiotherapy Service: A Review of the Reported Clinical Experience. Clinical Oncology (Royal College of Radiologists) 28,3:185-197.
Szyszko, T.A., Yip, C., Szlosarek, P., et al. (2016). The role of new PET tracers for lung cancer. Lung Cancer 94,7-14.
Ueda, Y., Oohira, S., Isono, M., et al. (2016). Asymmetric margin setting at the cranial and caudal sides in respiratory gated and non-gated stereotactic body radiotherapy for lung cancer. British Journal of Radiology 89,1059:20150499.